EL7.AI
StocksMediumUpdated×2•Originally published 27 October 2026•Updated 27 October 2026•
4 min read

Exosens revenue jumps 23.5% in third quarter as demand accelerates

Key Facts

1Revenue rose 18.0% in the nine months to 386.9 million euros, with like-for-like growth of 14.4%.
2Like-for-like growth accelerated to 20.5% in the third quarter, from 11.4% in the first half.
3Revenue in Detection & Imaging rose 23.7% to 120.0 million euros, while revenue in Intensification increased 15.5% to 267.8 million euros.
4Adjusted gross profit reached 194.9 million euros, while its margin as a share of sales declined to 50.4% from 51.2%.

Exosens said on October 27 that revenue rose 23.5% in the third quarter of 2026, accelerating nine-month growth to 18.0%, according to a company statement. Consolidated revenue reached 386.9 million euros for the period ended September 30, with like-for-like growth of 14.4%. Chief Executive Jerome Cerisier said revenue growth had "accelerated to 23.5% in the third quarter," adding that the company was on track to meet its revised full-year outlook. The performance followed like-for-like growth of 11.4% in the first half, highlighting an improvement in sales momentum in the third quarter. The company’s announcement focused on updating its revenue and operating performance outlook ahead of its full-year results.

Like-for-like revenue growth accelerated to 20.5% in the third quarter, compared with 11.4% in the first half, the company said. Like-for-like growth measures business performance excluding the effects of changes in the group’s scope and foreign exchange rates, and was below total revenue growth in the quarter. Over the nine months, revenue rose 18.0%, while like-for-like growth was 14.4%. The comparison shows that sales growth improved in the third quarter on both a total and like-for-like basis. Cerisier said the revenue trajectory supported the company’s annual guidance, which it raised in September.

Growth was spread across the company’s two segments, with faster performance in Detection & Imaging. Revenue in that segment rose 23.7% to 120.0 million euros over the nine months, while revenue in the Intensification segment increased 15.5% to 267.8 million euros. On a like-for-like basis, Detection & Imaging grew 14.1%, compared with 14.5% for Intensification, according to company data. This reflects a difference between total growth rates, which include the impact of acquisitions, and like-for-like growth in the two segments. The company had attributed first-half growth in Detection & Imaging to acquisitions completed in 2025 and like-for-like growth of 14.6%, supported by demand in defense, surveillance and nuclear instrumentation.

On profitability, adjusted gross profit reached 194.9 million euros in the nine months, up 16.1% from the comparable period. But the margin as a share of sales fell to 50.4% from 51.2% in the nine months of 2025. Exosens attributed the decline to product mix and recruitment costs at its U.S. facility. It said its revised annual guidance takes these operating effects into account. In the first half, the company reported revenue of 253.1 million euros, up 15.3% year on year and 11.4% on a like-for-like basis, while adjusted earnings before interest, taxes, depreciation and amortization reached 83.6 million euros, up 18.3%, with a margin of 33.0%.

Exosens raised its 2026 revenue outlook on September 17 to a range of 558–570 million euros, from 520–540 million, and lifted its adjusted earnings before interest, taxes, depreciation and amortization outlook to 186–192 million euros from 168–178 million. At the midpoint, the forecasts imply growth of about 20% in revenue and 25% in adjusted earnings compared with 2025. The company linked the revision to faster adoption of imaging technologies in drone and counter-drone applications and long-range surveillance, alongside continued momentum in nuclear instrumentation, particularly next-generation SMR reactor applications. It also said faster ramp-up of European production capacity for image intensifier tubes would help it meet global demand for advanced night-vision solutions ahead of schedule. During 2026, the company plans to double production capacity for cooled infrared cameras and triple capacity for thermal cameras.

The company expects capital expenditure to amount to about 9% of revenue, excluding capitalized research and development costs estimated at about 3% of revenue. In a commercial development, subsidiary Photonis Defense received its first delivery order for 1,600 BiNOD systems under a U.S. Army program, as part of a broader contract worth 352.6 million dollars announced in March 2026. The company expects to deliver the first products by the end of 2026, with most deliveries scheduled for 2027. The order is part of the defense demand backdrop the company cited among the reasons for raising its outlook. Exosens set February 22, 2027, as the date for publication of its 2026 full-year results, which will include guidance for the following year.